Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Berlau

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Safety|August 17, 2024
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety reviewEszter Czifrus, Daniel J Berlau
Expert Review of Neurotherapeutics|August 12, 2023
Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapyEszter Czifrus, Daniel J Berlau
Learning & Memory (Cold Spring Harbor, N.Y.)|December 6, 2003
Basolateral amygdala lesions do not prevent memory of context-footshock trainingDaniel J Berlau, James L McGaugh
Neurobiology of Learning and Memory|February 7, 2006
Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdalaDaniel J Berlau, James L McGaugh
Zentralblatt Fur Gynakologie|September 27, 2000
[Efficiency of conventional glass wool and SpermFertil columns with respect to ROS-reduction, leukocyte reduction, and CASA-generated sperm counts in semen]J Berlau, U C Hipler, G Schreiber
Expert Opinion on Pharmacotherapy|March 6, 2020
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeuticsSharon M Grages, Michael Bell, Daniel J Berlau
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 14, 1997
Influence of lectins on the infectivity of elementary bodies of Chlamydia trachomatis D IC CAL 8 by synovial cellsJ Berlau, A Ziemer, A Groh, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 5, 1999
Distribution of Acinetobacter species on skin of healthy humansJ Berlau, H Aucken, H Malnick, et al.
Expert Opinion on Pharmacotherapy|March 30, 2026
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an updateLeyken Wilson, Lucy M Johnson, Daniel J Berlau
Journal of Clinical Pathology|April 8, 1999
In situ hybridisation and direct fluorescence antibodies for the detection of Chlamydia trachomatis in synovial tissue from patients with reactive arthritisJ Berlau, U Junker, A Groh, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|August 17, 2024
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety reviewEszter Czifrus, Daniel J Berlau
Expert Review of Neurotherapeutics|August 12, 2023
Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapyEszter Czifrus, Daniel J Berlau
Learning & Memory (Cold Spring Harbor, N.Y.)|December 6, 2003
Basolateral amygdala lesions do not prevent memory of context-footshock trainingDaniel J Berlau, James L McGaugh
Neurobiology of Learning and Memory|February 7, 2006
Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdalaDaniel J Berlau, James L McGaugh
Zentralblatt Fur Gynakologie|September 27, 2000
[Efficiency of conventional glass wool and SpermFertil columns with respect to ROS-reduction, leukocyte reduction, and CASA-generated sperm counts in semen]J Berlau, U C Hipler, G Schreiber
Expert Opinion on Pharmacotherapy|March 6, 2020
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeuticsSharon M Grages, Michael Bell, Daniel J Berlau
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 14, 1997
Influence of lectins on the infectivity of elementary bodies of Chlamydia trachomatis D IC CAL 8 by synovial cellsJ Berlau, A Ziemer, A Groh, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 5, 1999
Distribution of Acinetobacter species on skin of healthy humansJ Berlau, H Aucken, H Malnick, et al.
Expert Opinion on Pharmacotherapy|March 30, 2026
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an updateLeyken Wilson, Lucy M Johnson, Daniel J Berlau
Journal of Clinical Pathology|April 8, 1999
In situ hybridisation and direct fluorescence antibodies for the detection of Chlamydia trachomatis in synovial tissue from patients with reactive arthritisJ Berlau, U Junker, A Groh, et al.
Pageof 5